Cytovance Biologics hires vp of sales and business development

Valerie McDonnell joins from Althea

Cytovance Biologics, a biopharmaceutical contract manufacturing company specialising in the production of therapeutic proteins and antibodies from mammalian cell culture, has appointed Valerie McDonnell as vice president of sales and business development.

McDonnell has more than 22 years’ experience in the biotech industry. Prior to joining Cytovance she was vice president of sales at Althea.

Before joining Althea she was a study director at BioReliance where she was responsible for client programmes in the Molecular Biology Department. She also worked at The Institute for Genomic Research (TIGR) and participated in the Haemophilus influenzae sequencing programme.

You may also like

Manufacturing

Avantor and Cytovance collaborate on plasmid DNA supply

The collaboration extends Avantor’s offering of critical materials for vaccines and therapeutics focused on cell and gene therapy
Manufacturing

Cytovance Biologics to expand microbial manufacturing

Has acquired 100L and 1,000L fermenters
Manufacturing

Cytovance Biologics to expand production capabilities in 2013

Installs a 1,000L SUB bioreactor, 5,000L stainless steel bioreactor and fill/finish line
Manufacturing

Cytovance adds 1,000L bioreactor to mammalian facility

Will complement existing manufacturing process trains in Oklahoma City
Manufacturing

AQUARIA - enhancing drying performance while reducing consumption

AQUARIA stands out within the diverse range of parts washers for the pharmaceutical industry that have been developed by IMA over the last two decades. Designed to ensure maximum performance in cleaning and validation with high efficiency, AQUARIA is renowned for its reduced consumption of energy, water, detergents and compressed air. These qualities match the pharmaceutical industry’s current attention to environmental issues and prove how IMA is actively supporting sustainability across a wide spectrum of processes, where its solutions represent a respected benchmark
Regulatory

The challenges of developing combination products

Regulatory complexity and the case for a holistic development strategy
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
Subscribe now